矩阵金属蛋白酶-7与COVID-19后持续的肺部异常有关
Ivette Buendia-Roldan1,2, Leslie Chavez-Galan1,2, Hiram Aguilar-Duran1
1Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico.
ERJ open research
|December 3, 2024
概括
在COVID-19后的患者中,矩阵金属蛋白酶-7 (MMP-7) 的增加与肺功能受损以及纤维化迹象的HRCT发现相关. 这表明MMP-7可能在长期COVID肺病进展中发挥作用.
科学领域:
- 肺部医学 肺部医学
- 生物标志物 生物标志物
- 放射学 放射学是一门学科.
背景情况:
- 后COVID-19综合征可以表现为持续的呼吸系统症状和肺部异常.
- 矩阵金属蛋白酶-7 (MMP-7) 与组织重塑和纤维化有关.
- 了解与肺部序列相关的生物标志物对于患者管理至关重要.
研究的目的:
- 调查MMP-7水平与COVID-19后患者肺部异常之间的关联.
- 探索MMP-7与气体交换功能之间的关系.
- 为了将MMP-7与高分辨率计算机断层扫描 (HRCT) 与肺纤维化暗示的发现相关联.
主要方法:
- 对后COVID-19患者的前性队列研究.
- 对血清MMP-7水平的测量.
- 肺功能测试评估气体交换.
- 高分辨率计算机断层扫描 (HRCT) 用于肺部结构评估.
主要成果:
- 在COVID-19后的患者中观察到MMP-7水平升高.
- 增加的MMP-7显著与气体交换受损有关.
- 较高的MMP-7度与微妙的HRCT发现相关,表明肺纤维化.
结论:
- 升高的MMP-7与COVID-19后患者的肺部异常有关.
- 在COVID-19后,MMP-7可能作为肺纤维化和功能障碍的潜在生物标志物.
- 需要进一步的研究来阐明MMP-7在COVID-19相关的肺部疾病中的作用.
相关概念视频
Pneumothorax-II
120
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
120
Role of Matrix Metalloproteases in Degradation of ECM
2.3K
Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult...
2.3K
Myocarditis III: Medical Management
1
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
1
Myocarditis II: Clinical features and Diagnostic Tests
1
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
1
Pneumonia II: Pathophysiology
216
The pathophysiology of pneumonia involves the following steps:
216


